TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized Study Of High Dose 3D-CRT/IMRT Versus Standard Dose 3D-CRT/IMRT In Patients Treated For Localized Prostate Cancer
Brief Summary: RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. It is not yet known which dose of radiation therapy is more effective in treating stage II prostate cancer.

PURPOSE: Randomized phase III trial to compare the effectiveness of two different doses of specialized radiation therapy in treating patients who have stage II prostate cancer.


Options:
A: Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
B: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Radiation: 3-dimensional conformal radiation therapy, Radiation: intensity-modulated radiation therapy | Arm Label: Arm II; Type: EXPERIMENTAL; Interventions: Radiation: 3-dimensional conformal radiation therapy, Radiation: intensity-modulated radiation therapy | Intervention Type: RADIATION; Name: 3-dimensional conformal radiation therapy; Assigned to Arm(s): Arm I, Arm II | Intervention Type: RADIATION; Name: intensity-modulated radiation therapy; Assigned to Arm(s): Arm I, Arm II
C: Arm Label: Intensity Modulated Radiotherapy (IMRT); Type: ACTIVE_COMPARATOR; Interventions: Radiation: Conventional Fractionated Intensity Modulated Radiotherapy | Arm Label: Hypofractionated Intensity Modulated Radiotherapy (HIMRT); Type: EXPERIMENTAL; Interventions: Radiation: Hypofractionated Intensity Modulated Radiotherapy | Intervention Type: RADIATION; Name: Conventional Fractionated Intensity Modulated Radiotherapy; Assigned to Arm(s): Intensity Modulated Radiotherapy (IMRT) | Intervention Type: RADIATION; Name: Hypofractionated Intensity Modulated Radiotherapy; Assigned to Arm(s): Hypofractionated Intensity Modulated Radiotherapy (HIMRT)
D: Arm Label: 70.2 Gy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: 70.2 Gy 3D-CRT/IMRT | Arm Label: 79.2 Gy; Type: EXPERIMENTAL; Interventions: Radiation: 79.2 Gy 3D-CRT/IMRT | Intervention Type: RADIATION; Name: 70.2 Gy 3D-CRT/IMRT; Assigned to Arm(s): 70.2 Gy | Intervention Type: RADIATION; Name: 79.2 Gy 3D-CRT/IMRT; Assigned to Arm(s): 79.2 Gy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized Phase III Study of Adjuvant Oncophage® Versus Observation in Subjects With High Risk of Recurrence After Surgical Treatment for Renal Cell Carcinoma
Brief Summary: Determine whether patients receiving adjuvant HSPPC-96 treatment after surgically resected, locally advanced renal cell carcinoma have improved recurrence-free survival as compared to subjects with no adjuvant treatment.


Options:
A: Arm Label: Cohort A: MSI Positive Colorectal Cancer; Type: EXPERIMENTAL; Interventions: Drug: MK-3475 | Arm Label: Cohort B: MSI Negative Colorectal Cancer; Type: EXPERIMENTAL; Interventions: Drug: MK-3475 | Arm Label: Cohort C: MSI Positive Non-Colorectal Cancer; Type: EXPERIMENTAL; Interventions: Drug: MK-3475 | Intervention Type: DRUG; Name: MK-3475; Assigned to Arm(s): Cohort A: MSI Positive Colorectal Cancer, Cohort B: MSI Negative Colorectal Cancer, Cohort C: MSI Positive Non-Colorectal Cancer
B: Intervention Type: DRUG; Name: autologous human tumor-derived HSPPC-96; Assigned to Arm(s): N/A
C: Arm Label: 1: AGS-003+sunitinib; Type: EXPERIMENTAL; Interventions: Biological: AGS-003, Drug: Sunitinib | Intervention Type: BIOLOGICAL; Name: AGS-003; Assigned to Arm(s): 1: AGS-003+sunitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): 1: AGS-003+sunitinib
D: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Open-Label, Comparative Study to Compare the Efficacy and Safety of Levofloxacin and Standard of Care Therapy in the Treatment of Children With Community-Acquired Pneumonia in the Hospitalized or Outpatient Setting
Brief Summary: The purpose of this study is to determine the safety and efficacy of levofloxacin in the treatment of children with community acquired pneumonia.


Options:
A: Intervention Type: DRUG; Name: Oral Co-trimoxazole (8mg/kg/day trimithoprim) twice a day for five days vs. oral amoxycillin (20 mg/kg/day) thrice a day for three days.; Assigned to Arm(s): N/A
B: Arm Label: amoxicillin/clavulanic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amoxycillin/clavulanic acid | Arm Label: ceftriaxone/oxacillin; Type: ACTIVE_COMPARATOR; Interventions: Drug: ceftriaxone/oxacillin | Intervention Type: DRUG; Name: Amoxycillin/clavulanic acid; Assigned to Arm(s): amoxicillin/clavulanic acid | Intervention Type: DRUG; Name: ceftriaxone/oxacillin; Assigned to Arm(s): ceftriaxone/oxacillin
C: Arm Label: Intervention; Type: OTHER; Interventions: Drug: Amoxicillin | Arm Label: Control; Type: OTHER; Interventions: Other: Referral to Health facility | Intervention Type: DRUG; Name: Amoxicillin; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Referral to Health facility; Assigned to Arm(s): Control
D: Intervention Type: DRUG; Name: Levofloxacin; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy and Safety of Risperidone in Adolescents With Schizophrenia: a Comparison of Two Dose Ranges of Risperidone
Brief Summary: A clinical study to compare the safety and effectiveness of two different dose ranges of risperidone solution in the treatment of adolescents with a diagnosis of schizophrenia.


Options:
A: Arm Label: olanzapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine (enrollment closed in this treatment) | Arm Label: risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: molindone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Molindone | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): risperidone | Intervention Type: DRUG; Name: Olanzapine (enrollment closed in this treatment); Assigned to Arm(s): olanzapine | Intervention Type: DRUG; Name: Molindone; Assigned to Arm(s): molindone
B: Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy (CBT); Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Supportive Counselling (SC); Assigned to Arm(s): N/A
C: Arm Label: In SHAPE; Type: EXPERIMENTAL; Interventions: Behavioral: In SHAPE, Behavioral: Fitness Club Membership | Arm Label: Fitness Club Membership; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Fitness Club Membership | Intervention Type: BEHAVIORAL; Name: In SHAPE; Assigned to Arm(s): In SHAPE | Intervention Type: BEHAVIORAL; Name: Fitness Club Membership; Assigned to Arm(s): Fitness Club Membership, In SHAPE
D: Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy and Safety of Risperidone in Adolescents With Schizophrenia: a Comparison of Two Dose Ranges of Risperidone
Brief Summary: A clinical study to compare the safety and effectiveness of two different dose ranges of risperidone solution in the treatment of adolescents with a diagnosis of schizophrenia.


Options:
A: Arm Label: Aripiprazole 10 mg/day Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole tablet, 10 mg | Arm Label: Aripiprazole 30 mg/day Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aripiprazole tablet, 30 mg | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo tablet | Intervention Type: DRUG; Name: Aripiprazole tablet, 10 mg; Assigned to Arm(s): Aripiprazole 10 mg/day Group | Intervention Type: DRUG; Name: Aripiprazole tablet, 30 mg; Assigned to Arm(s): Aripiprazole 30 mg/day Group | Intervention Type: DRUG; Name: Placebo tablet; Assigned to Arm(s): Placebo Group
B: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Quetiapine Fumarate; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Randomized Pilot Study to Evaluate the Effects of Galantamine and Donepezil on Sleep and Attention and Gastrointestinal (GI) Tolerance in Patients With Mild to Moderate Alzheimer's Disease (AD)
Brief Summary: The purpose of this study is to evaluate the relative effects of galantamine compared to donepezil (both cholinesteraste inhibitors), on sleep, attention, and gastrointestinal tolerance in patients with Alzheimer's disease.


Options:
A: Arm Label: Zolpidem CR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Zolpidem CR | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Zolpidem CR; Assigned to Arm(s): Zolpidem CR | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: galantamine; Assigned to Arm(s): N/A
C: Arm Label: Trazodone; Type: EXPERIMENTAL; Interventions: Drug: Trazodone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Trazodone; Assigned to Arm(s): Trazodone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Treatment Group; Type: EXPERIMENTAL; Interventions: Device: GammaSense Stimulation System (Active Settings) | Arm Label: Control Group; Type: SHAM_COMPARATOR; Interventions: Device: GammaSense Stimulation System (Sham Settings) | Intervention Type: DEVICE; Name: GammaSense Stimulation System (Active Settings); Assigned to Arm(s): Treatment Group | Intervention Type: DEVICE; Name: GammaSense Stimulation System (Sham Settings); Assigned to Arm(s): Control Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Safety and Efficacy Trial of LJP 394 in Systemic Lupus Erythematosus (SLE) Patients With a History of Renal Disease
Brief Summary: The purpose of this study is to determine whether LJP 394 (abetimus sodium) is safe and effective in delaying and reducing renal flares in patients with lupus nephritis.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: AMG 811 | Arm Label: AMG811; Type: OTHER; Interventions: Drug: AMG 811 | Intervention Type: DRUG; Name: AMG 811; Assigned to Arm(s): AMG811, Placebo
B: Arm Label: Tacrolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: tacrolimus | Arm Label: mycophenolate mofetil; Type: ACTIVE_COMPARATOR; Interventions: Drug: mycophenolate mofetil | Intervention Type: DRUG; Name: tacrolimus; Assigned to Arm(s): Tacrolimus | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): mycophenolate mofetil
C: Arm Label: FK506+MMF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Multitherapy | Intervention Type: DRUG; Name: Multitherapy; Assigned to Arm(s): FK506+MMF
D: Intervention Type: DRUG; Name: Abetimus sodium (LJP 394); Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Study of Olanzapine Plus Fluoxetine in Combination for Treatment-Resistant Depression Without Psychotic Features
Brief Summary: The purposes of this study are to determine:

* Whether olanzapine plus fluoxetine in combination will help patients with treatment-resistant major depression.
* The safety of olanzapine plus fluoxetine in combination, plus and any side effects that might be associated with the combination.
* The effectiveness of olanzapine plus fluoxetine compared to olanzapine and fluoxetine alone.


Options:
A: Arm Label: lithium plus usual care; Type: EXPERIMENTAL; Interventions: Drug: lithium | Arm Label: usual care without lithium therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: usual care | Intervention Type: DRUG; Name: lithium; Assigned to Arm(s): lithium plus usual care | Intervention Type: DRUG; Name: usual care; Assigned to Arm(s): usual care without lithium therapy
B: Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): N/A
C: Arm Label: Phase B; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712 + ADT, Drug: Placebo + ADT | Arm Label: Phase A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + ADT | Intervention Type: DRUG; Name: OPC-34712 + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase A
D: Arm Label: A1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole+ ADT | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo+ ADT | Intervention Type: DRUG; Name: Aripiprazole+ ADT; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo+ ADT; Assigned to Arm(s): A2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this clinical research study is to support earlier observations that Glucovance controls glucose levels after a mean, and improves overall glucose control better than metformin or glyburide therapy alone in adults with type 2 diabetes.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Comparator: MK0431 100 mg q.d. (q.d. = once daily) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: Metformin 500 mg b.i.d. | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Comparator: Metformin 1000 mg b.i.d. | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily), Drug: Comparator: Metformin 500 mg b.i.d. | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily), Drug: Comparator: Metformin 1000 mg b.i.d. | Arm Label: 6; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo (Phase A)/Metformin (Phase B) | Arm Label: 7; Type: EXPERIMENTAL; Interventions: Drug: Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d. | Intervention Type: DRUG; Name: Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily); Assigned to Arm(s): 4, 5 | Intervention Type: DRUG; Name: Comparator: MK0431 100 mg q.d. (q.d. = once daily); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator: Placebo (Phase A)/Metformin (Phase B); Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: Comparator: Metformin 500 mg b.i.d.; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d.; Assigned to Arm(s): 7 | Intervention Type: DRUG; Name: Comparator: Metformin 1000 mg b.i.d.; Assigned to Arm(s): 3, 5
B: Arm Label: metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glipizide | Arm Label: glipizide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Intervention Type: DRUG; Name: Glipizide; Assigned to Arm(s): metformin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): glipizide
C: Intervention Type: DRUG; Name: Glucovance (metformin HCl/glyburide); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: or Metformin HCl alone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: or Glyburide alone.; Assigned to Arm(s): N/A
D: Arm Label: Metformin alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Glargine followed by Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Glargine | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Glargine followed by Metformin, Metformin alone | Intervention Type: DRUG; Name: Glargine; Assigned to Arm(s): Glargine followed by Metformin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Research Study in Patients With Persistent Macular Edema Due to Diabetic Retinopathy, Retinal Vein Occlusion, Uveitis, or Irvine-Gass Syndrome
Brief Summary: The purpose of this clinical research study is to evaluate the safety and effectiveness of an investigational medication to treat macular edema that persists despite current treatment methods. Participants will be evaluated for improvement in vision and side effects.

Macular edema is a condition that affects the back of the eye (retina). It frequently occurs in people who have a history of diabetes, and is also associated with high blood pressure, uveitis, and previous eye surgery. The main symptom of macular edema is decreased vision, generally a blurring of central vision.

There are no direct costs to participants for assessments and treatment as defined in the study protocol. All candidates must be available for required scheduled visits during the trial's 6-month follow-up period. Although the disease called age-related macular degeneration (AMD) affects the same region of the eye as macular edema, they are not the same condition and AMD is not studied in this research trial.


Options:
A: Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluocinolone acetonide intraocular implant | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: oral corticosteroid with immunosuppressive agents as needed | Intervention Type: DRUG; Name: fluocinolone acetonide intraocular implant; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: oral corticosteroid with immunosuppressive agents as needed; Assigned to Arm(s): 2
C: Arm Label: Fluocinolone acetonide 0.59mg; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Fluocinolone acetonide 2.1mg; Type: EXPERIMENTAL; Interventions: Drug: Fluocinolone acetonide 2.1mg | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide 0.59mg | Intervention Type: DRUG; Name: Fluocinolone acetonide 2.1mg; Assigned to Arm(s): Fluocinolone acetonide 2.1mg
D: Arm Label: Fluocinolone acetonide; Type: EXPERIMENTAL; Interventions: Drug: fluocinolone acetonide intravitreal implant | Arm Label: Standard care; Type: ACTIVE_COMPARATOR; Interventions: Drug: corticosteroids and immunosuppressants | Intervention Type: DRUG; Name: fluocinolone acetonide intravitreal implant; Assigned to Arm(s): Fluocinolone acetonide | Intervention Type: DRUG; Name: corticosteroids and immunosuppressants; Assigned to Arm(s): Standard care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Research Study in Patients With Persistent Macular Edema Due to Diabetic Retinopathy, Retinal Vein Occlusion, Uveitis, or Irvine-Gass Syndrome
Brief Summary: The purpose of this clinical research study is to evaluate the safety and effectiveness of an investigational medication to treat macular edema that persists despite current treatment methods. Participants will be evaluated for improvement in vision and side effects.

Macular edema is a condition that affects the back of the eye (retina). It frequently occurs in people who have a history of diabetes, and is also associated with high blood pressure, uveitis, and previous eye surgery. The main symptom of macular edema is decreased vision, generally a blurring of central vision.

There are no direct costs to participants for assessments and treatment as defined in the study protocol. All candidates must be available for required scheduled visits during the trial's 6-month follow-up period. Although the disease called age-related macular degeneration (AMD) affects the same region of the eye as macular edema, they are not the same condition and AMD is not studied in this research trial.


Options:
A: Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Triamcinolone, Bevacizumab; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: triamcinolone acetonide; Assigned to Arm(s): N/A
D: Arm Label: Ranibizumab 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser, Procedure: Sham laser | Arm Label: Ranibizumab 0.5 mg + laser; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser | Arm Label: Laser; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Procedure: Laser, Drug: Sham to ranibizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Laser; Assigned to Arm(s): Laser, Ranibizumab 0.5 mg, Ranibizumab 0.5 mg + laser | Intervention Type: PROCEDURE; Name: Sham laser; Assigned to Arm(s): Ranibizumab 0.5 mg | Intervention Type: DRUG; Name: Sham to ranibizumab; Assigned to Arm(s): Laser

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Research Study in Patients With Persistent Macular Edema Due to Diabetic Retinopathy, Retinal Vein Occlusion, Uveitis, or Irvine-Gass Syndrome
Brief Summary: The purpose of this clinical research study is to evaluate the safety and effectiveness of an investigational medication to treat macular edema that persists despite current treatment methods. Participants will be evaluated for improvement in vision and side effects.

Macular edema is a condition that affects the back of the eye (retina). It frequently occurs in people who have a history of diabetes, and is also associated with high blood pressure, uveitis, and previous eye surgery. The main symptom of macular edema is decreased vision, generally a blurring of central vision.

There are no direct costs to participants for assessments and treatment as defined in the study protocol. All candidates must be available for required scheduled visits during the trial's 6-month follow-up period. Although the disease called age-related macular degeneration (AMD) affects the same region of the eye as macular edema, they are not the same condition and AMD is not studied in this research trial.


Options:
A: Arm Label: Ranibizumab; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab | Arm Label: Laser; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Laser photocoagulation | Arm Label: Laser with Ranibizumab; Type: EXPERIMENTAL; Interventions: Drug: Ranibizumab, Procedure: Laser photocoagulation | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Laser with Ranibizumab, Ranibizumab | Intervention Type: PROCEDURE; Name: Laser photocoagulation; Assigned to Arm(s): Laser, Laser with Ranibizumab
B: Arm Label: Cohort with routine OCT monitoring; Type: N/A; Interventions: N/A | Arm Label: Cohort without routine OCT monitoring; Type: N/A; Interventions: N/A
C: Intervention Type: DRUG; Name: DEX PS DDS®; Assigned to Arm(s): N/A
D: Arm Label: Ranibizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Drug: Bevacizumab | Arm Label: Bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ranibizumab, Drug: Bevacizumab | Intervention Type: DRUG; Name: Ranibizumab; Assigned to Arm(s): Bevacizumab, Ranibizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab, Ranibizumab

Answer: C